Regardless of the precise pharmacological approach, the findings in our CHIP−/−-mouse model argue that the up-regulation of the adiponectin-AMPK-FOXO-signaling pathway may be therapeutically beneficial in the presently explosive diabetes/obesity-associated NAFLD/NASH epidemic. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.